title: Pharmacogenomics of anti-platelet and anti-coagulation therapy.
abstract: Arterial thrombosis is a major component of vascular disease, especially myocardial infarction (MI) and stroke. Current anti-thrombotic therapies such as warfarin and clopidogrel are effective in inhibiting cardiovascular events; however, there is great inter-individual variability in response to these medications. In recent years, it has been recognized that genetic factors play a significant role in drug response, and, subsequently, common variants in genes responsible for metabolism and drug action have been identified. These discoveries along with new diagnostic targets and therapeutic strategies hold promise for more effective individualized anti-coagulation and anti-platelet therapy.
authors.affiliation: Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, and the Program in Personalized and Genomic Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA. Adam.Fisch@som.umaryland.edu
authors.forename: Adam S
authors.initials: AS
authors.lastname: Fisch
authors.forename: Christina G
authors.initials: CG
authors.lastname: Perry
authors.forename: Sarah H
authors.initials: SH
authors.lastname: Stephens
authors.forename: Richard B
authors.initials: RB
authors.lastname: Horenstein
authors.forename: Alan R
authors.initials: AR
authors.lastname: Shuldiner
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D000077144:Clopidogrel; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D013927:Thrombosis / Q000235:genetics* / Q000517:prevention & control*; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome; D014859:Warfarin / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D014859:Warfarin; D000077144:Clopidogrel; D013988:Ticlopidine